Notice: fwrite(): Write of 263 bytes failed with errno=122 Disk quota exceeded in /home/pharmac7/public_html/jobs.pharmacyconnect.co.za/wp-admin/includes/class-wp-filesystem-direct.php on line 76

Author name: antonheyman

Launch of JANUMET® – combination sitagliptin and metformin hydrochloride

New Product: MSD has launched JANUMET® which is an addition to the recent introduction of JANUVIA®. The two fall into the same portfolio of new oral antidiabetic agent for the treatment of type 2 diabetes. JANUVIA® contains sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor (incretin enhancer) that increases the levels of two incretin hormones, glucagon-like

Launch of JANUMET® – combination sitagliptin and metformin hydrochloride Read More »

Out of stock notification: Sofradex® 8ml Reg. No.: H 1482 (Act 101/1965)

Sanofi would like to assure you that this out-of-stock situation of Sofradex® is temporary and at present, we are actively and earnestly endeavouring to make sure that we will have stock of Sofradex® 8ml available as soon as possible to prevent any further disruption and inconvenience. Should you have any further queries, please contact our

Out of stock notification: Sofradex® 8ml Reg. No.: H 1482 (Act 101/1965) Read More »

Seroquel XR® – Launch of New Indication for MDD & New 150 mg (30’s) Pack

Seroquel XR 150mg® is now launched and is indicated as adjunctive therapy in the treatment of resistant major depressive disorder. It should be administered once daily in the evening, with or without food, and swallowed whole and not split, chewed or crushed. The initial dose for major depressive disorder should begin at 50mg on Day

Seroquel XR® – Launch of New Indication for MDD & New 150 mg (30’s) Pack Read More »